The Courier-Mail

Starpharma tips speedy drug delivery after deal


BIOTECH Starpharma expects global biopharmac­eutical group AstraZenec­a to move quickly to get a cancer drug under joint developmen­t into clinical trials and then on to market.

Starpharma has signed a licensing deal with AstraZenec­a under which the latter will use the Australian biotech’s drug delivery technology in the developmen­t and commercial­isation of a new cancer drug, followed by other compounds. The licensing agreement could generate up to $180 million in signature and milestone payments for Starpharma in relation to the first product and up to $133 million for each subsequent product.

Starpharam­a shares closed 4 lower at 70 yesterday. They soared more than 21 per cent on Monday after the AstraZenec­a deal was announced.

Newspapers in English

Newspapers from Australia